Brief: Femasys Completes First In-Office Commercial Procedure With FDA-Cleared FemaSeed Infertility Solution
06/03/2024 14:27
March 6 (Reuters) - Femasys Inc FEMY.O :
* FEMASYS COMPLETES THE FIRST IN-OFFICE COMMERCIAL PROCEDURE
WITH
THE FDA-CLEARED FEMASEED INFERTILITY SOLUTION
* FEMASYS INC: FEMASEED TOP-LINE PIVOTAL DATA EXPECTED TO BE
ANNOUNCED DURING Q1 2024
Source text for Eikon: ID:nGNX5twhTH
Further company coverage: FEMY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Femasys
See all newsBrief: Femasys - Files For Resale Of Up To 28,124,997 Shares Of Common Stock - SEC Filing
Brief: Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc
Femasys Inc reports results for the quarter ended June 30 - Earnings Summary
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview